ClinicalTrials.gov
public full text
Public Domain
Comparative Expression of ER,PR and HER2/Neu in Initial and Recurrent Breast Cancer.
Expression of ER, PR and HER2/neu in initial and recurrent breast cancer and correlate the results to different clinical and pathological parameters as patient age,sex, tumor location, status of nodal involvement and lymphovascular invasion
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- ESR1 Mutations in Asian ER+ Metastatic Breast Cancer on Hormonal Therapy-based Treatments#889057
- Re-expression of ER in Triple Negative Breast Cancers#1231408
- Phase II Study With the Trifunctional Antibody Ertumaxomab to Treat Metastatic Breast Cancer Progressing After Endocrine Treatment#911008
- Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer#891283
- Unravelling the role of Extracellular Vesicles carrying CD133 in breast cancer invasion and metastasis#1066205
Record · ID 1408921
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive